Intas And Arecor Ally On Value-Added Development

Accord To Market Reformulated Product Based On Arestat Proprietary Technology

Intas and Arecor have struck an exclusive licensing deal that will see the pair use Arecor’s proprietary Arestat formulation technology to develop value-added medicines, in particular for use outside of the hospital setting.

Value Added Dial Knob Turn
Intas and Arecor are focusing on adding value • Source: Alamy

Intas and Arecor have announced that they are collaborating on developing value added medicines, after striking an exclusive licensing deal that will see the pair use Arecor’s proprietary Arestat formulation technology to develop an unspecified reformulated product, with a particular focus on making it suitable to be used by patients outside of the hospital setting.

Announcing the deal – financial terms of which were not disclosed – Intas said the collaboration “will see the development...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business